FMEA Stock Chart & Stats
€19.70
-€0.20(-0.94%)
At close: 4:00 PM EDT
€19.70
-€0.20(-0.94%)
Day’s Range― - ―
52-Week Range€17.20 - €23.60
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
€10.21B
Enterprise Value€24.57K
Total Cash (Recent Filing)€1.45B
Total Debt (Recent Filing)€10.96B
Price to Earnings (P/E)11.9
Beta0.39
Next Earnings
Nov 03, 2026EPS Estimate
0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding537,129,300
10 Day Avg. Volume0
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.83
Price to Sales (P/S)0.60
P/FCF Ratio6.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.34Price Target Upside3.25% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)2.02
Revenue Forecast (FY)€19.31B
Bulls Say, Bears Say
Bulls Say
Recurring Integrated Kidney-care ModelFresenius Medical Care combines recurring dialysis treatments with dialysis equipment, pharmaceuticals and consumables. This vertical integration supports predictable demand, operational synergies and cross-selling across its own clinics and external providers.
Sustainable Margin ImprovementThe combination of operating-income growth, margin expansion and recurring transformation savings indicates improved cost discipline. If maintained, these efficiencies can support profitability and cash generation even with broadly flat revenue.
5008X Technology And Clinical DifferentiationThe 5008X rollout strengthens Fresenius's technology ecosystem and consumables opportunity across its clinic base. Growing clinical adoption and reported quality improvements may reinforce provider preference and support long-term treatment differentiation.
Bears Say
Weak U.S. Treatment VolumesThe U.S. is central to the clinic business, so declining same-market treatments constrain volume-driven revenue growth. The referral-capture execution gap and flat volume outlook suggest that operational remediation may take time.
China Regulatory And Cost PressureRegulatory changes and tender pressure can reduce product access, pricing and market growth in China. Combined with inflation in materials and logistics, these factors could keep Care Enablement earnings under pressure beyond a single quarter.
Moderate Leverage And Incomplete Margin RecoveryLeverage is manageable but higher than recent levels while declining equity reduces balance-sheet flexibility. Profitability has improved, yet margins have not fully recovered, leaving earnings and reinvestment capacity sensitive to operating setbacks.
Fresenius Medical Care News
FMEA FAQ
What was Fresenius Medical Care Corp.’s price range in the past 12 months?
Fresenius Medical Care Corp. lowest stock price was €17.20 and its highest was €23.60 in the past 12 months.
What is Fresenius Medical Care Corp.’s market cap?
Fresenius Medical Care Corp.’s market cap is €10.21B.
When is Fresenius Medical Care Corp.’s upcoming earnings report date?
Fresenius Medical Care Corp.’s upcoming earnings report date is Nov 03, 2026 which is in 49 days.
How were Fresenius Medical Care Corp.’s earnings last quarter?
Fresenius Medical Care Corp. released its earnings results on Aug 03, 2026. The company reported €0.561 earnings per share for the quarter, beating the consensus estimate of €0.534 by €0.027.
Is Fresenius Medical Care Corp. overvalued?
According to Wall Street analysts Fresenius Medical Care Corp.’s price is currently Undervalued.
Does Fresenius Medical Care Corp. pay dividends?
Fresenius Medical Care Corp. does not currently pay dividends.
What is Fresenius Medical Care Corp.’s EPS estimate?
Fresenius Medical Care Corp.’s EPS estimate is 0.53.
How many shares outstanding does Fresenius Medical Care Corp. have?
Fresenius Medical Care Corp. has 537,129,300 shares outstanding.
What happened to Fresenius Medical Care Corp.’s price movement after its last earnings report?
Fresenius Medical Care Corp. reported an EPS of €0.561 in its last earnings report, beating expectations of €0.534. Following the earnings report the stock price went up 1.835%.
Which hedge fund is a major shareholder of Fresenius Medical Care Corp.?
Currently, no hedge funds are holding shares in DE:FMEA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fresenius Medical Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
€20.34 (3.25% Upside)
€20.34 (3.25% Upside)
Blogger Sentiment
Neutral
DE:FMEA Sentiment 50%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-5.89%
12-Months-Change
Fundamentals
Return on Equity
3.77%
Trailing 12-Months
Asset Growth
-2.60%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fresenius Medical Care Corp.
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
FMEA Company Deck
FMEA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced meaningful operational and financial progress against notable execution and external headwinds. Highlights include strong operating income growth (+23%), margin expansion (+180 bps), EUR 67 million of sustainable FME25+ savings, improved cash generation (+11% operating cash flow), a successful 5008X rollout (227 clinics, >600k treatments) and a profitable turnaround in value-based care (EUR 18m operating income). Lowlights include a U.S. referral/capture execution gap driving a 0.9% decline in U.S. same‑market treatments and an expectation that U.S. volumes will remain around the Q2 level for 2026, regulatory and inflationary pressures in China and Care Enablement (EUR ~20m Q2 headwind), a EUR 103m special-item charge (TAVNEOS impairment), and TDAPA timing creating an H2 earnings headwind (net ~EUR 50m for the year). Overall, the positives around profitability, cash flow, capital returns and product rollout outweigh the near-term volume and regulatory challenges, though execution on U.S. referrals and China strategy will be key to sustaining momentum.View all DE:FMEA earnings summariesFMEA Stock 12 Month Forecast
Average Price Target
€20.34
▲(3.25% Upside)